Sangamo files Ch 11, sells key capsid/gene therapy assets to Eli Lilly and Astellas

SANGAMO THERAPEUTICS, INC

Sangamo filed Chapter 11 bankruptcy and signed asset sale agreements with Eli Lilly and Astellas Gene Therapies.
Lilly's subsidiary is stalking horse bidder for capsids (STAC-150, STAC-BBB), SIFTER, MINT, and zinc finger prion assets.
Astellas acquires assets under separate agreement; terms not disclosed in this filing.
Sangamo common stock delisted from Nasdaq on May 5, 2026; now trading on OTCQB.
Sale subject to Bankruptcy Court approval and potential higher bids in auction process.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.